Motexafin gadolinium  (Synonyms: PCI 0120; Gadolinium texaphyrin; Gd-Tex)

Motexafin gadolinium (PCI 0120) is a potent antitumor agent. Motexafin gadolinium is a specific texaphyrin in complex with gadolinium(III). Motexafin gadolinium increases intracellular ROS production. Motexafin gadolinium enhances sensitivity of tumor cells to ionizing radiation^[1][2][3].

Motexafin gadolinium (50 µM; 22 h) leads to dichlorofluorescein acetate (DCFA) oxidation in A549 cells^[1].
Motexafin gadolinium (100 µM; 4, 12 h) increases intracellular ROS production and apoptosis (24 h) when combined with Zn (100 μM), and ascorbate (100 μM) in Ramos lymphoma cells^[2].
Motexafin gadolinium (0.01-100 μM) dose-dependent decrease the expression of p53 protein in HF-1 cells when combined with Zn (100 μM), and ascorbate (100 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1148.40

C₅₂H₇₂GdN₅O₁₄

246252-06-2

CC([O-][Gd+3]1234([N-]5C6=C(CC)C(CC)=C5C=C7[N]1=C(C(C)=C7CCCO)C=[N]2C8=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C8[N]3=CC(C(C)=C9CCCO)=[N]4C9=C6)[O-]C(C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Magda D, et al. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 2006 Dec;16(6):466-76.  [Content Brief]

  [2]. Singh AT, et al. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010 Apr;30(4):1131-6.  [Content Brief]

  [3]. Evens AM, et al. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res. 2009 Oct 15;15(20):6462-71.  [Content Brief]